Hypersensitivity reaction in the US Food and Drug Administration-approved second-generation drug-eluting stents: histopathological assessment with ex vivo optical coherence tomography

Circulation. 2015 Jan 20;131(3):322-4. doi: 10.1161/CIRCULATIONAHA.114.012658.

Authors

Fumiyuki Otsuka¹, Kazuyuki Yahagi¹, Elena Ladich¹, Robert Kutys¹, Russell Alexander¹, David Fowler¹, Renu Virmani¹, Michael Joner²

Affiliations

¹ From CVPath Institute Inc, Gaithersburg, MD (F.O., K.Y., E.L., R.K., R.V., M.J.); and Office of the Chief Medical Examiner, Baltimore, MD (R.A., D.F.).
² From CVPath Institute Inc, Gaithersburg, MD (F.O., K.Y., E.L., R.K., R.V., M.J.); and Office of the Chief Medical Examiner, Baltimore, MD (R.A., D.F.). mjoner@cvpath.org.

PMID: 25601953
DOI: 10.1161/CIRCULATIONAHA.114.012658

No abstract available

Publication types

Case Reports

MeSH terms

Drug Hypersensitivity / diagnosis*
Drug Hypersensitivity / etiology
Drug-Eluting Stents / adverse effects*
Humans
Male
Middle Aged
Sirolimus / adverse effects
Sirolimus / analogs & derivatives*
Tomography, Optical Coherence / methods*
United States
United States Food and Drug Administration / legislation & jurisprudence*

Substances

zotarolimus
Sirolimus